相关实验视频
Updated: May 20, 2025

05:47
Animal Models of Depression - Chronic Despair Model CDM
Published on: September 23, 2021
7.1K
利用基于抑郁症症状的表型来探索重度抑郁症中胺治疗反应:Bio-K多中心试验
Brandan K Penaluna1, Jennifer L Vande Voort1, William V Bobo2
1Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America.
Journal of affective disorders
|May 17, 2025
概括
胺注射改善了治疗耐药性抑郁症 (TRD) 的四种表型中的抑郁症状. 然而,积极的悲伤表型与较低的缓解率有关,这表明需要针对TRD进行个性化治疗方法.
科学领域:
- 精神病学和神经科学 精神病学和神经科学
- 药理学 药理学是指药理学的学科.
- 临床心理学 临床心理学
背景情况:
- 四个相关的抑郁症表型 (悲伤,消极思想,兴趣/活动,神经素质) 之前使用蒙哥马利-阿斯伯格抑郁症评分表 (MADRS) 确定.
- 治疗耐药性抑郁症 (TRD) 是一个重大挑战,需要探索新的治疗策略.
研究的目的:
- 为了研究静脉注射 (IV) 胺在治疗治疗耐治疗抑郁症 (TRD) 患者群体中的不同抑郁症表型中的疗效.
- 分析基因胺剂后的四种MADRS衍生的表型的治疗反应和缓解率.
主要方法:
- 一项多中心,开放性临床试验 (BioK) 的二次分析,涉及75名TRD患者 (18-65岁).
- 患者在11天内接受了三次静脉胺注射,并继续接受先前的治疗.
- 使用MADRS评估抑郁症症状,表型分为积极或消极;缓解定义为MADRS<10注射后#3.
主要成果:
- 在急性治疗阶段结束时,整体缓解率为53%.
- 在所有四种表型中都观察到平均因子得分的显著下降.
- 悲伤表型的缓解率较低,特别是基线得分较高 (OR = 0.32,p = 0.04),神经素质表型的反应最少.
结论:
- 在TRD患者中,急性IV胺治疗在四种抑郁症表型中显示出有效性.
- 一个积极的悲伤表型可能表明急性IV胺的缓解率降低.
- 在急性治疗阶段结束时,在抗抑郁药反应中没有发现任何显著的性别差异.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
173
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
173
Depression: Overview
204
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
204
Depressive Disorders: MDD and Dysthymia
27
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
27
Electroconvulsive Therapy
20
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
20
Depressive Disorders: Etiology
26
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
26

